News

PredictImmune and CEO Paul Kinnon announced as finalists in the Cambridge Independent Science and Technology Awards 2019 Cambridge, UK, September...

PredictImmune appoints Tim Rea of BGF as non-executive director Experienced entrepreneur and investor appointed with immediate effect Cambridge, UK,...

PredictImmune closes Series B funding round, raising £10M to further accelerate global commercial expansion and support expanding product pipeline...

Gut publication extends follow-up for PredictImmune’s blood-based prognostic biomarker in IBD. Cambridge, UK, 2nd May 2019:  Longer-term follow-up...

PredictImmune’s first prognostic test for IBD, PredictSURE IBD™, launches in the UK and Irelandpe The world’s first validated prognostic test for...

PredictImmune’s first prognostic test, PredictSURE IBD™, set for UK and European launch having been awarded CE mark Achievement marks significant...

Crohn’s Disease PROFILE Trial Protocol Published Cambridge, UK, 06 December 2018: The PROFILE trial is the first biomarker-stratified study in...

PredictImmune joins the British In vitro Device Association (BIVDA) Cambridge, UK, 13th November 2018: With the launch of its first product...

PredictImmune: Announced as Finalist in the Cambridge Independent Science & Technology Awards Cambridge, UK, 14th September 2018:  PredictImmune...